Emerald Mutual Fund Advisers Trust Has $21.47 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Emerald Mutual Fund Advisers Trust lowered its position in NeoGenomics, Inc. (NASDAQ:NEO) by 0.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,547,895 shares of the medical research company’s stock after selling 10,000 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in NeoGenomics were worth $21,469,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Blue Trust Inc. raised its holdings in NeoGenomics by 107.2% during the 2nd quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock worth $32,000 after buying an additional 1,206 shares during the period. Burkett Financial Services LLC acquired a new position in shares of NeoGenomics in the fourth quarter valued at approximately $46,000. Quadrant Capital Group LLC raised its holdings in shares of NeoGenomics by 22.0% during the fourth quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after acquiring an additional 883 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of NeoGenomics by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock worth $136,000 after acquiring an additional 1,791 shares during the period. Finally, Banque Cantonale Vaudoise raised its holdings in shares of NeoGenomics by 10.2% during the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock worth $244,000 after acquiring an additional 1,633 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $16.04 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.93 and a current ratio of 2.01. The stock has a 50 day moving average price of $15.60 and a 200 day moving average price of $14.94. The stock has a market capitalization of $2.05 billion, a PE ratio of -24.30 and a beta of 1.19. NeoGenomics, Inc. has a 52 week low of $11.03 and a 52 week high of $21.22.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company had revenue of $164.50 million during the quarter, compared to the consensus estimate of $161.82 million. During the same quarter in the prior year, the firm posted ($0.09) EPS. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. Analysts predict that NeoGenomics, Inc. will post -0.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NEO. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. Benchmark reiterated a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Stephens reissued an “overweight” rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.89.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.